Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.